详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/ PD-L1 therapy

158| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Pharmacy,Sichuan Cancer Hospital and Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,China, [2]Department of Clinical Research,Sichuan Cancer Hospital and Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,China,

出处：

DOI：

ISSN：

关键词： chronic obstructive pulmonary disease (COPD) immune checkpoint inhibitors (ICIs) PD-1/PD-L1 lung cancer (LC) tumor immune microenvironment (TIME)

摘要：

Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are two of the most fatal respiratory diseases, seriously threatening human health and imposing a heavy burden on families and society. Although COPD is a significant independent risk factor for LC, it is still unclear how COPD affects the prognosis of LC patients, especially when LC patients with COPD receive immunotherapy. With the development of immune checkpoint inhibition (ICI) therapy, an increasing number of inhibitors of programmed cell death-1 (PD-1) and PD-1 ligand (PD-L1) have been applied to the treatment of LC. Recent studies suggest that LC patients with COPD may benefit more from immunotherapy. In this review, we systematically summarized the outcomes of LC patients with COPD after anti-PD-1/PD-L1 treatment and discussed the tumor immune microenvironment (TIME) regulated by COPD in LC immunotherapy, which provides novel insights for the clinical treatment of LC patients with COPD.Copyright © 2022 Lin, Huang, Chen, Xiao and Wang.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2022]版：

Q1 IMMUNOLOGY

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 7.3 出版当年[2022版] 8 出版当年五年平均 8.787 出版前一年[2021版] 5.7 出版后一年[2023版]

第一作者：

第一作者机构： [1]Department of Pharmacy,Sichuan Cancer Hospital and Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,China,

通讯作者：

通讯机构： [2]Department of Clinical Research,Sichuan Cancer Hospital and Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,China,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy [2]PD-1/PD-L1在食管鳞状细胞癌中的表达及临床意义 [3]中国PD-1/PD-L1抑制剂治疗肺癌临床试验概况 [4]PD-1/PD-L1抑制剂在妇科肿瘤的研究进展 [5]结直肠癌pd-1和pd-l1信号通路及免疫治疗研究现状与进展 [6]PD-1/PD-L1与食管鳞癌治疗和预后的相关性研究进展 [7]PD-1/PD-L1与食管鳞癌治疗和预后的相关性研究进展 [8]Association between chronic obstructive pulmonary disease and cardiovascular disease in adults aged 40 years and above: data from NHANES 2013-2018 [9]Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis [10]PD-1/PD-L1在肝细胞癌治疗中的研究进展